about
Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma.Cytotoxic activity of ten algae from the Persian Gulf and Oman Sea on human breast cancer cell lines; MDA-MB-231, MCF-7, and T-47DGenetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study.Umbelliprenin is cytotoxic against QU-DB large cell lung cancer cell line but anti-proliferative against A549 adenocarcinoma cellsHelper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors.Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes.A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.A gene-disease association study of IL18 in thyroid cancer: genotype and haplotype analyses.Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors.Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma.Comparative Proteomics of Sera From HCC Patients With Different Origins.Long Chain Alkyl Esters of Hydroxycinnamic Acids as Promising Anticancer Agents: Selective Induction of Apoptosis in Cancer Cells.Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population.Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients.Carthamus, Salvia and Stachys species protect neuronal cells against oxidative stress-induced apoptosis.Proteome-scale identification of Leishmania infantum for novel vaccine candidates: A hierarchical subtractive approach.Structural vaccinology considerations for in silico designing of a multi-epitope vaccine.Chemokine and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7.Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial.Association of PDCD1 gene markers with susceptibility to thyroid cancer.Anticancer activity assessment of two novel binuclear platinum (II) complexes.CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis.Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients.IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression.Intercellular adhesion molecule-1 genetic markers (+241G/A and +469A/G) in Iranian women with breast cancer.Program death 1 (PD1) haplotyping in patients with breast carcinoma.CTLA4 gene variations and haplotypes in patients with lung cancer.Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study.Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer.Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancerctla-4 gene variations may influence cervical cancer susceptibilityCTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancersCytotoxic T lymphocyte antigen-4 promoter variants in breast cancerPD-1 Haplotype Combinations and Susceptibility of Patients to Squamous Cell Carcinomas of Head and NeckAssociation of PD-1 gene with outcome of hepatitis C virus infection.Interleukin13 haplotypes and susceptibility of Iranian women to breast cancerSDF-1 and CCR5 genes polymorphism in patients with head and neck cancerProgrammed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer
P50
Q34638359-330FB168-FD4F-4B1E-8B25-388839A4D4C6Q34646640-EA033B38-CA3F-4EFB-B326-32A8F1620FBAQ35172218-9BDE055A-1C4A-4266-9288-53CF0DC563F5Q35991106-2AD80908-224A-44BF-A6F6-A5DD75756A59Q36565008-89C129C3-815E-4BA0-8457-07502AB27C75Q39817335-30624ACF-E951-4874-B7C7-A6DDD5524FA3Q39980089-FF9301D7-6ED4-44B3-B43E-B54CAFBF9D1CQ40093563-6A3E41CF-43C7-4C5A-B1F3-901F710EA14FQ40871471-433F2F8F-0D55-4574-B2D1-3067DF20055CQ41297736-9FA7B8E3-72D5-4DB1-A046-864E65AF3C90Q41706256-42261C51-1003-445C-BD1B-14DD5974D3C1Q41905396-AAC8EE39-9DB6-4494-8C74-9DB430FE47F5Q42799010-2597796A-91C1-4D60-BEFD-4F1801F35767Q44211775-163F2780-FCAB-46B2-BAA5-9E7E5D3B26F3Q45224110-CA952D90-303A-4504-B085-74D0FF249B37Q46835604-39C3774D-3BE2-4869-B055-47534CEA26DAQ47240519-CC5C108B-FF9B-41A8-A358-18A8A9299C66Q47280738-6EA95403-D54C-4002-9BB5-568735532E12Q47906862-1D3887EA-1AC4-4BA1-A8AD-687BBF72CF00Q48053306-C99550D7-BF79-4921-8EF0-C20648DA5655Q51273001-31BC7267-1A20-4E81-9D0F-C931097592F6Q51707460-4C92E9F2-8704-4865-A937-4244E078587DQ51811390-E6099701-D95F-46BA-9864-54D3E5CC635AQ52094012-15AD7FF7-1B2C-49AD-8AF1-1EC199B57572Q53075829-1D4EC932-B0AA-46C7-8624-B4190C4F398CQ53477813-7808F7FF-690D-4C57-8636-5A9898522F82Q54399945-338BE780-EE9A-46CC-8A5B-032651891BBFQ54445924-86A307AB-2FFC-480D-89EE-2AA540277D63Q54459486-660160A5-9E00-4E27-AA61-F7DABDFA669DQ54471401-1B9D1CC8-8955-496D-B71B-3813C2A36334Q54658995-21D9367A-4EEE-489E-BC78-6A7AA4A21EADQ56899352-3A969D52-EBA1-46B8-8B8B-1EFA3CE6DCFCQ56899389-3DA97114-D5F6-4198-9F1C-FC58A957990DQ56900986-35447BAF-2E4A-4BF3-A820-81CD8A44C2B7Q56902308-3901D20E-A535-4D69-9942-0B78553204B3Q58095425-5D6926BA-9B9A-42B3-ABBF-B5FBA3BCCF76Q64942493-B75B5D51-0377-4567-B52D-EAABBED47F85Q79804716-C10DAC15-44B1-4F48-8954-69D61A0F3E17Q81009170-FA6BE68F-762F-41F4-98FA-ECC7870B4D83Q84794316-309E02EF-4209-4D41-A2EF-950E060B22A0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nasrollah Erfani
@ast
Nasrollah Erfani
@en
Nasrollah Erfani
@es
Nasrollah Erfani
@nl
Nasrollah Erfani
@sl
type
label
Nasrollah Erfani
@ast
Nasrollah Erfani
@en
Nasrollah Erfani
@es
Nasrollah Erfani
@nl
Nasrollah Erfani
@sl
altLabel
Saeed Erfani
@en
prefLabel
Nasrollah Erfani
@ast
Nasrollah Erfani
@en
Nasrollah Erfani
@es
Nasrollah Erfani
@nl
Nasrollah Erfani
@sl
P1053
C-9376-2011
P106
P1153
8663943500
P31
P3829
P496
0000-0002-4158-9128